Publications by authors named "T M Sissung"
Underrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib in self-identified Black women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer. LEANORA (NCT04657679) was a prospective, observational, multicenter cohort study involving 14 Black women.
View Article and Find Full Text PDFUnderrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib in self-identified Black women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer. LEANORA (NCT04657679) was a prospective, observational, multicenter cohort study involving 14 Black women.
View Article and Find Full Text PDFBackground/aim: Gonadotropin-releasing hormone 2 (GNRH2) is a poorly-studied peptide hormone that is widely distributed in the central nervous system and expressed in peripheral tissues of mammals. The non-synonymous rs6051545 variant in GNRH2 (A16V) has been linked to higher serum testosterone concentrations. This study investigated whether the A16V variant is associated with altered androgen-deprivation therapy (ADT) progression-free survival (PFS) and overall survival (OS).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the combination of chemotherapy and DNA damage response (DDR) inhibitors, focusing on using tumor-targeted chemotherapy to minimize toxicities.
- A phase I trial tested sacituzumab govitecan, an antibody-drug conjugate, with the ATR inhibitor berzosertib, involving twelve patients at increasing dose levels.
- The treatment showed improved safety with no severe adverse effects, leading to favorable tumor regressions in some patients, suggesting a promising new approach for better delivering cancer therapies.